The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals

Jozef J P Nauta1, Iris A de Bruijn

  • 1Solvay Pharmaceuticals, Clinical Development Influenza Vaccines, P.O. BOX 900, 1380 DA Weesp, The Netherlands. jos.nauta@solvay.com

Vaccine
|June 27, 2006
PubMed

Related Concept Videos